NOVA Novo Nordisk A/S ADS

NOVO NORDISK 72 HOUR DEADLINE ALERT: APPROXIMATELY 72 HOURS REMAIN; FORMER LOUISIANA ATTORNEY GENERAL AND KAHN SWICK & FOTI, LLC REMIND INVESTORS of Deadline in Class Action Lawsuit Against Novo Nordisk A/S – (NVO)

Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with large financial interests that they have only until March 13, 2017 to file lead plaintiff applications in a securities class action lawsuit against Novo Nordisk A/S (NYSE: NVO). Investor losses must relate to purchases of the Company’s American Depositary Receipts (“ADRs”) between February 5, 2015 and October 27, 2016. This action is pending in the United States District Court for the District of New Jersey.

What You May Do

If you purchased ADRs of Novo Nordisk and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, call toll free at 1-877-515-1850 or email KSF Managing Partner Lewis Kahn ([email protected]). If you wish to serve as a lead plaintiff in this class action by overseeing lead counsel with the goal of obtaining a fair and just resolution, you must request this position by application to the Court by March 13, 2017.

About Kahn Swick & Foti, LLC

KSF, whose partners include the Former Louisiana Attorney General Charles C. Foti, Jr., is a law firm focused on securities, antitrust and consumer class actions, along with merger & acquisition and breach of fiduciary litigation against publicly traded companies on behalf of shareholders. The firm has offices in New York, California and Louisiana.

To learn more about KSF, you may visit www.ksfcounsel.com.

EN
11/03/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Novo Nordisk A/S ADS

 PRESS RELEASE

ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Be...

NEW YORK--(BUSINESS WIRE)-- , a leading national securities law firm, is investigating potential claims against Novo Nordisk A/S (“Novo Nordisk” or the “Company”) (NYSE: NVO) and reminds investors of the March 25, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See . As detailed below, the complaint...

Novo Nordisk A/S: Update following rating upgrade to Aa3

Our credit view of this issuer reflects its strong credit metrics.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

Novo Nordisk A/S - June 2024 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch